Analysis of clinical efficacy of dapagliflozin combined with sitagliptin phosphate in the treatment of patients with diabetes nephropathy
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NETL
NSTL
维普
万方数据
目的 分析达格列净联合磷酸西格列汀治疗糖尿病肾病患者的临床疗效.方法 206 例糖尿病肾病患者,按随机数字表法分为对照组(104 例)和观察组(102 例).对照组患者给予磷酸西格列汀+盐酸二甲双胍治疗,观察组患者给予磷酸西格列汀+达格列净片治疗.比较两组治疗前后血糖[空腹血糖(FBG)、餐后 2 h血糖(2 h PBG)、糖化血红蛋白(HbA1c)]监测值和肾功能[血肌酐(Scr)、尿素氮(BUN)]及治疗效果、不良反应发生情况.结果 治疗前两组患者FBG、2 h PBG、HbA1c、Scr、BUN比较无差异(P>0.05);治疗后两组FBG、2 h PBG、HbA1c、Scr、BUN均低于治疗前,且观察组FBG(5.21±1.01)mmol/L、2 h PBG(7.80±1.71)mmol/L、HbA1c(6.22±1.59)%、Scr(332.18±111.71)μmol/L、BUN(17.22±1.59)mmol/L显著低于对照组的(6.78±2.41)mmol/L、(8.89±2.29)mmol/L、(8.33±1.94)%、(555.43±173.29)μmol/L、(23.11±3.94)mmol/L(P<0.05).观察组总有效率 98.04%(100/102)高于对照组的86.54%(90/104)(P<0.05).两组治疗过程中未见不良反应发生情况.结论 磷酸西格列汀联合达格列净对于糖尿病肾病的治疗效果确切,可更好的控制血糖和改善肾功能,安全性高,值得推广.
Objective To analyze the clinical efficacy of dapagliflozin combined with sitagliptin phosphate in the treatment of patients with diabetes nephropathy.Methods A total of 206 patients with diabetes nephropathy were randomly divided into a control group(104 cases)and an observation group(102 cases)by random number table.Patients in the control group were given sitagliptin phosphate + metformin hydrochloride,and patients in the observation group were given sitagliptin phosphate + dapagliflozin tablets.The blood glucose[fasting plasma glucose(FBG),2-h postprandial blood glucose(2 h PBG),glycated hemoglobin(HbA1c)]monitoring values,renal function[serum creatinine(Scr),blood urea nitrogen(BUN)]before and after treatment,therapeutic effect,and occurrence of adverse reactions were compared between the two groups of patients.Results Before treatment,there were no differences in FBG,2 h PBG,HbA1c,Scr and BUN between the two groups(P>0.05).After treatment,FBG,2 h PBG,HbA1c,Scr and BUN in both groups were lower than those before treatment;the observation group had FBG of(5.21±1.01)mmol/L,2 h PBG of(7.80±1.71)mmol/L,HbA1c of(6.22±1.59)%,Scr of(332.18±111.71)μmol/L and BUN of(17.22±1.59)mmol/L,which were significantly lower than(6.78±2.41)mmol/L,(8.89±2.29)mmol/L,(8.33±1.94)%,(555.43±173.29)μmol/L and(23.11±3.94)mmol/L in the control group(P<0.05).The total effective rate of the observation group was 98.04%(100/102),which was higher than 86.54%(90/104)of the control group(P<0.05).No adverse reactions were observed in the two groups during treatment.Conclusion Sitagliptin phosphate combined with dapagliflozin has a definite therapeutic effect on diabetes nephropathy,which can better control blood glucose and improve renal function,and has high safety,and is worthy of promotion.
DapagliflozinSitagliptin phosphateDiabetes nephropathyBlood glucoseRenal function
NETL
NSTL
维普
万方数据
